Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
14 February 2018
Question for written answer
to the Commission
Rule 130
Frédérique Ries (ALDE)

 Subject:  Better monitoring of prescribed medicines

It is hard to believe, but the mere fact of not taking the right medicine at the right time, and appropriately combined with other molecules in the correct dosage, is responsible for 200 000 deaths a year in the EU. The estimated cost to national social security systems is around EUR 125 billion, which highlights the importance of combating the problem of patients not taking their prescribed medicine, a problem which affects one in every two patients.

The US Food and Drug Administration (FDA) has just come up with a response to this phenomenon by authorising the placing on the market of the first digital pill capable of telling whether, and when, patients have taken their medicine. This tracking system, which comprises a sensor embedded in a pill that communicates with a wearable patch, is authorised for treatment of schizophrenia, acute mania and bipolar disorder.

Is the Commission aware of such a medical innovation in the EU? Does it consider that such a tracking system should be promoted in the EU in order to ensure the correct ingestion of medication by targeted patient populations, such as people suffering from a mental illness or a neurodegenerative disorder?

Original language of question: FR 
Last updated: 28 February 2018Legal notice